we have a name

World Health Organisation assigns CUV1647 generic name
CUV1647 to be known as “afamelanotide”
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce that its
photo protective drug, CUV1647, has been designated the name “afamelanotide” by the World Health
Organisation (WHO). Clinuvel will use the name “afamelanotide” rather than “CUV1647” in future
documentation.

Generic names issued by the WHO are international and non-proprietary in nature (INN). Afamelanotide will
be universally used to describe the active pharmaceutical substance Nle4-D-Phe7 alpha-Melanocyte
Stimulating Hormone developed by Clinuvel.
With this designation, afamelanotide becomes the universally applicable generic name for Nle4-D-Phe7 alpha-
Melanocyte Stimulating Hormone (CUV1647), the molecular name used thus far for the photo protective drug
being exclusively developed by Clinuvel.

Afamelanotide will be included in the international list of acknowledged pharmaceuticals (pharmacopeia), on a
medicinal label and product information.
Dr Philippe Wolgen, Clinuvel’s CEO said today: “This is another step towards commercialization of our drug. In
afamelanotide the WHO has assigned a distinct generic name and pharmaceutical identifier to facilitate
recognition by future medical prescribers of our photo protective drug. The next step is to arrive at a brand
name which will fully cover the properties and medical benefits of afamelanotide.”